Home Cart Sign in  
Chemical Structure| 68047-06-3 Chemical Structure| 68047-06-3

Structure of 4-Hydroxytamoxifen
CAS No.: 68047-06-3

Chemical Structure| 68047-06-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4-Hydroxytamoxifen is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer.

Synonyms: trans-4-Hydroxytamoxifen; (Z)-Afimoxifene; ICI 79280

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 4-Hydroxytamoxifen

CAS No. :68047-06-3
Formula : C26H29NO2
M.W : 387.51
SMILES Code : OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(C3=CC=CC=C3)\CC)C=C1
Synonyms :
trans-4-Hydroxytamoxifen; (Z)-Afimoxifene; ICI 79280
MDL No. :MFCD00278780

Safety of 4-Hydroxytamoxifen

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 cells 0.1 µM 24 hours To investigate the effect of 4-OHT on TGF-α mRNA expression, results showed that 4-OHT modestly reduced TGF-α mRNA levels PMC2150359
MDA-MB-231 BC-2 cells 0.1 µM 24 hours To investigate the induction of TGF-α mRNA expression by 4-OHT, results showed that 4-OHT stimulated accumulation of TGF-α mRNA in a concentration-dependent manner, with higher levels than in S30 cells PMC2150359
MDA-MB-231 S30 cells 0.1 µM 24 hours To investigate the induction of TGF-α mRNA expression by 4-OHT, results showed that 4-OHT stimulated accumulation of TGF-α mRNA in a concentration-dependent manner PMC2150359
MDA-MB-435S cells 17.5 μM 24 hours To evaluate the inhibitory effects of SK and 4-OHT on the proliferation of MDA-MB-435S cells, results showed that SK had a more potent inhibitory effect on MDA-MB-435S cells than on MCF-7 cells. PMC7063777
MCF-7 cells 15 μM 24 hours To evaluate the inhibitory effects of SK and 4-OHT on the proliferation of MCF-7 cells, results showed that 4-OHT had a more potent inhibitory effect on MCF-7 cells than on MDA-MB-435S cells. PMC7063777
Human MDA-MB-231 breast cancer cells 1 μM 24 hours 4-Hydroxytamoxifen up-regulated the expression of p27 using pathway #1 which consisted mainly of receptor tyrosine kinases and mTORC1 PMC3180262
MDA-MB-231 human breast cancer cells 1 μM 24 hours Up-regulated expression of p27 and inhibited G1-to-S phase transition of the cell cycle PMC2841156
MCF7 human breast cancer cells 1 μM 24 hours Up-regulated expression of p27 and inhibited G1-to-S phase transition of the cell cycle PMC2841156
MCF7 1 μM 24-72 hours To evaluate the antiproliferative effect of 4-OHT and anti-miR-21 co-loaded nanoparticles on MCF7 cells. Results showed that co-loaded nanoparticles significantly inhibited MCF7 cell growth at 1 μM concentration, outperforming free 4-OHT and untreated cells. PMC4687493
MCF-7 cells 0.01-1.00 nM 3 weeks To evaluate the effect of 4-Hydroxytamoxifen on colony formation of MCF-7 cells, showing significant stimulation at low concentrations. PMC2033516
HEK293 cells 1–6 µM 30 minutes To study the glucuronidation activity of UGT1A4 against 4-hydroxytamoxifen, results showed significant glucuronidation activity of UGT1A4 against trans-4-OH-TAM and cis-4-OH-TAM PMC1779459
Vero E6 cells 10 μM 36 hours Detected GFP expression levels to assess the replication capacity of recombinant VSV PMC10040539
BHK-T7 cells 10 μM 48 hours Used for recombinant VSV recovery, 4-HT induces intein splicing to restore VSV replication PMC10040539
4T1 1 μM 5 days To evaluate the antiproliferative effect of 4-OHT and anti-miR-21 co-loaded nanoparticles on 4T1 cells. Results showed that co-loaded nanoparticles significantly inhibited 4T1 cell growth at 1 μM concentration, outperforming free 4-OHT and untreated cells. PMC4687493
BT-474 1 μM 5 days To evaluate the antiproliferative effect of 4-OHT and anti-miR-21 co-loaded nanoparticles on BT-474 cells. Results showed that co-loaded nanoparticles significantly inhibited BT-474 cell growth at 1 μM concentration, outperforming free 4-OHT and untreated cells. PMC4687493
ZR-75-1 1 μM 5 days To evaluate the antiproliferative effect of 4-OHT and anti-miR-21 co-loaded nanoparticles on ZR-75-1 cells. Results showed that co-loaded nanoparticles significantly inhibited ZR-75-1 cell growth at 1 μM concentration, outperforming free 4-OHT and untreated cells. PMC4687493
IMR90 ER:RAS cells 100 nM 5 to 10 days Induction of oncogene-induced senescence (OIS) to study the role of TLR2 in senescence PMC6551188
BT-474 0.05–10 μM 96 hours To evaluate the effect of 4-Hydroxytamoxifen on the viability of BT-474 cells. Results showed that the IC50 value of 4-Hydroxytamoxifen after 96 hours of treatment was 5.7 μM. PMC4819954
T47D 0.05–10 μM 96 hours To evaluate the effect of 4-Hydroxytamoxifen on the viability of T47D cells. Results showed that the IC50 value of 4-Hydroxytamoxifen after 96 hours of treatment was 4.2 μM. PMC4819954

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Intracerebral injection model Intraperitoneal injection 0.4 μg/g Once daily for 5 days Evaluated the regulatory effect of 4-HT on recombinant VSV LC599 replication in mice, showing that 4-HT significantly enhanced viral replication PMC10040539
BALB/c nude mice HR+HER2− breast cancer xenograft model Subcutaneous injection 250 mg/kg Once per week for 6 weeks SMAD4 depletion induced endocrine resistance PMC11196642
Mice ΑMHC-MerCreMer transgenic mice Intraperitoneal injection 20 mg/kg 5 or 10 consecutive days To evaluate the effects of OH-Txf on cardiac function, results showed that OH-Txf did not deteriorate cardiac function PMC7864833

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.58mL

0.52mL

0.26mL

12.90mL

2.58mL

1.29mL

25.81mL

5.16mL

2.58mL

References

 

Historical Records

Categories